Fulcrum Therapeutics will release Q3 2025 financial results on October 29 and host a conference call at 8:00 a.m. ET.
Quiver AI Summary
Fulcrum Therapeutics, Inc. announced that it will release its third quarter 2025 financial results on October 29, 2025, prior to the opening of U.S. financial markets. The company's management will conduct a conference call and webcast at 8:00 a.m. ET on the same day to discuss the financial outcomes and recent corporate developments. Participants can register for the call to receive access details, and the event will also be available as a replay afterward. Fulcrum Therapeutics focuses on developing small molecules to benefit patients with genetically defined rare diseases, with its leading program, pociredir, aimed at treating sickle cell disease by increasing fetal hemoglobin expression. Additional information about the company can be found on its website and social media platforms.
Potential Positives
- Fulcrum Therapeutics is set to release its third quarter 2025 financial results, which could provide important insights into the company's financial health and performance.
- The management conference call will offer updates on recent corporate developments, potentially signaling progress or advancements in their clinical programs.
- The focus on developing therapies for genetically defined rare diseases demonstrates the company's commitment to addressing high unmet medical needs, potentially enhancing its reputation in the biopharmaceutical industry.
- Fulcrum's lead clinical program, pociredir, targets a significant health issue—sickle cell disease—highlighting the company's role in addressing critical healthcare challenges.
Potential Negatives
- Management's need for a conference call to discuss financial results may indicate underlying issues with transparency or performance that they feel necessitate direct communication.
- The lack of detailed financial information in the press release might raise concerns among investors regarding the company's current financial status and performance metrics.
FAQ
When will Fulcrum Therapeutics release its Q3 2025 financial results?
Fulcrum Therapeutics will release its Q3 2025 financial results on October 29, 2025, before U.S. financial markets open.
What time is the Fulcrum Therapeutics conference call?
The conference call will be held at 8:00 a.m. ET on October 29, 2025.
How can I access the conference call for Fulcrum Therapeutics?
To access the conference call, register through the provided link to receive dial-in details and a unique PIN.
Where can I find the archived replay of the conference call?
The archived replay will be available on the Investor Relations section of Fulcrum Therapeutics' website after the live webcast.
What is Fulcrum Therapeutics' primary focus?
Fulcrum Therapeutics focuses on developing small molecules to improve the lives of patients with genetically defined rare diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FULC Insider Trading Activity
$FULC insiders have traded $FULC stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $FULC stock by insiders over the last 6 months:
- GREG TOURANGEAU (Principal Accounting Officer) sold 498 shares for an estimated $2,519
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FULC Hedge Fund Activity
We have seen 55 institutional investors add shares of $FULC stock to their portfolio, and 63 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,589,000 shares (+53.0%) to their portfolio in Q2 2025, for an estimated $10,932,320
- BALYASNY ASSET MANAGEMENT L.P. added 1,338,214 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,206,912
- GOLDMAN SACHS GROUP INC added 740,936 shares (+184.0%) to their portfolio in Q2 2025, for an estimated $5,097,639
- D. E. SHAW & CO., INC. added 596,050 shares (+102.7%) to their portfolio in Q2 2025, for an estimated $4,100,824
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 534,394 shares (-11.1%) from their portfolio in Q2 2025, for an estimated $3,676,630
- POINT72 ASSET MANAGEMENT, L.P. added 498,219 shares (+inf%) to their portfolio in Q2 2025, for an estimated $3,427,746
- ADAR1 CAPITAL MANAGEMENT, LLC removed 437,183 shares (-89.1%) from their portfolio in Q2 2025, for an estimated $3,007,819
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FULC Analyst Ratings
Wall Street analysts have issued reports on $FULC in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 07/29/2025
- Piper Sandler issued a "Overweight" rating on 05/29/2025
- Leerink Partners issued a "Outperform" rating on 05/23/2025
- Cantor Fitzgerald issued a "Overweight" rating on 05/15/2025
To track analyst ratings and price targets for $FULC, check out Quiver Quantitative's $FULC forecast page.
$FULC Price Targets
Multiple analysts have issued price targets for $FULC recently. We have seen 6 analysts offer price targets for $FULC in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- Andrew S. Fein from HC Wainwright & Co. set a target price of $12.0 on 10/20/2025
- Luca Issi from RBC Capital set a target price of $5.0 on 07/30/2025
- Edward Tenthoff from Piper Sandler set a target price of $9.0 on 05/29/2025
- Joseph Schwartz from Leerink Partners set a target price of $12.0 on 05/23/2025
- Kristen Kluska from Cantor Fitzgerald set a target price of $10.0 on 05/15/2025
Full Release
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2025 financial results will be released on Wednesday, October 29, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Individuals may register for the conference call by clicking the link here . Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here . Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit
www.fulcrumtx.com
and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
[email protected]
617-283-2856
